2022 Transplant Hepatology Board Review Course
Image For Activity Cover
4 Courses
Member: $350.00
Non-Member: $540.00
Patient: Not Eligible
Associate: $260.00
Student: $115.00
Early Career: $350.00
Industry Rep: $775.00
Credit Offered
9.25 AMA PRA Category 1 Credits
9.25 CE Credits
9.25 ABIM MOC Points
9 ABP-MOC Points
  • Description:
  • Accreditation Information
  • Faculty and Disclosures
  • AASLD Privacy Policy
  • Recommended

The 2022 AASLD Transplant Hepatology Board Review Course was released on Friday, August 15, 2020 as an on-demand course.

This course will help prepare physicians for the American Board of Internal Medicine (ABIM) and American Board of Pediatrics (ABP) certification and maintenance of certification (MOC) exam in transplant hepatology and pediatric transplant hepatology as it reflects the updated ABIM/ABP Transplant Hepatology Certification Exam blueprint. High yield clinical topics will be presented by leaders in the field of hepatology and transplant medicine. Designed for ABIM/ABP Transplant Hepatology exam preparation, the course also provides a comprehensive review of up-to-date management of liver transplant patients.

COMPONENTS: Online presentations comprised of PowerPoint slides and accompanying audio, online pre- and post-tests and evaluations: - 25 online, narrated presentations 20 - 45 minutes in length  - MOC quiz questions for each session - Evaluation for CME credit/ABIM and ABP MOC point offerings 

DIRECTIONS: Review all section tabs before you begin. Start watching the presentation videos. Complete necessary components to claim either CME and ABIM and or ABP MOC.

HANDOUTS: To access, download and print the PDFs of each presentation, please head to the Handouts tab.  Note, you will need to download the PDF to your device to proceed with printing. 


Continuing Medical Education (CME): 9.25 AMA PRA Category 1 Credits™ ABIM Maintenance of Certification (MOC): 9.25 ABIM MOC Points ABP Maintenance of Certification (MOC): 9.00 ABP MOC Points

Release Date: October 15, 2022
Expiration Date: October 15, 2024

Accreditation Statement: 
The American Association for the Study of Liver Diseases is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement:
The American Association for the Study of Liver Diseases designates this enduring material activity for a maximum of 9.25 AMA PRA Category 1 CreditsTM . Physicians should only claim the credit commensurate with the extent of their participation in the activity. 

To claim both CME Credits and ABIM and or ABP MOC points for this activity you must:
• Watch each video presentation
• Complete each session post-test and pass with a score of 70% or higher (Participants have unlimited attempts to earn the passing score)
• Complete the Final Evaluation

Claim CME credits (ABIM Rule: MOC points must be equivalent to the amount of CME credits claimed for the activity)
MOC completions are collected on the 15th of each month and submitted to the ABIM by the last day of the month. Points are not submitted automatically and will not display immediately on your ABIM MOC Profile. MOC points are available for ABIM and or ABP board certified physicians only.

This online, OnDemand educational activity has been planned in accordance with AASLD and ACCME Standards of Commercial Support by members of the AASLD Transplant Hepatology Board Review Course faculty, the AASLD Maintenance of Certification Committee and the AASLD Governing Board. As an accredited provider, AASLD must collect information from all planners, faculty, and others in the planning and control of continuing medical education (CME) activities to disclose all their financial relationships with ineligible companies within the prior 24 months. Ineligible companies are those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose financial relationships with ineligible companies regardless of their view of the relevance of the relationship to the education.

Statement on off-label and investigational use: Faculty are asked to make a reasonable effort to identify during their presentation any discussion of off-label or investigative use or application of a product or device. Financial disclosures will appear at the beginning of each session and are provided below.

Faculty Disclosures

Scott Biggins, MD, MAS, FAASLD Grants/Research Support: Novartis Research

Peter Chin-Hong, MD Grants/Research Support: Karius

Janice Jou, MD, MHS, FAASLD Nothing to disclose.

Binita Kamath, MBBChir Scientific Consulting: Albireo, Mirum, Audentes (Astellas)

Laura Kulik, MD Speakers Bureau: Gilead Scientific Consulting: Eisai, Exelixis, Genetech

Jennifer Lai, MD, MBA Grants/Research Support: Vir Biotechnology, Axcella Health, Inc., Lipocine, Gore Medical

Josh Levitsky, MD, MS, FAASLD, FAST Grants/Research Support: Novartis Scientific Consulting: Mallinkrodt

Joseph Lim, MD, FAASLD Grants/Research Support: TARGET PharmaSolutions, Viking, Eiger; Leadership in related society: American College of Gastroenterology - Practice Parameters


Jessica Mellinger, MD Grants/Research Support: Salix Pharmaceuticals

Willscott Naugler, MD, FAASLD Nothing to disclose.

Jody Olson, MD Scientific Consulting: Mallinckrodt pharmaceuticals single time advisory board. Not an ongoing relationship

Mary Rinella, MD, FAASLD Nothing to disclose.

Mark Russo, MD, MPH, FAASLD Data Safety Monitoring Board for Industry or Commercial Enterprises: Moderna

Monika Sarkar, MD, MAS Grants/Research Support: I am the site PI for a clinical trial of an agent to treat NAFLD in women with polycystic ovary syndrome, sponsored by Zydus Pharmaceuticals. Funds received are solely used for research support.

Amit Singal, MD, MS, FAASLD Scientific Consulting: Bayer Pharmaceuticals, Eisai, Exelixis, FujiFilm/Wako Diagnostics

Debra Sudan, MD Nothing to disclose.

Shareef Syed, MBChB Nothing to disclose.

Ryan Taylor, MD, FAASLD Consulting for Equity (e.g. Venture Capital Firms): Abbive, Inc. Speakers Bureau: Gilead Sciences, Inc.

Amy Taylor, MD Nothing to disclose.

Gregory Tiao, MD Nothing to disclose.

Pamela L. Valentino, MD Nothing to disclose.

Elizabeth Verna, MD, MS Grants/Research Support: Salix Pharmaceuticals

Planner Disclosures

AASLD Maintenance of Certification Committee

Yumi Ando, MD Nothing to disclose.

Virginia C. Clark, MD, MS Grants/Research Support: Arrowhead Pharma, Genfit

Adam C. Deising, DO Nothing to disclose.

Nicole Gray, CNP Nothing to disclose.

Dina Halegoua-De Marzio, MD Scientific Consulting: Intercept

Adam James Hanje, MD, FAASLD Commercial Speaker's Bureau: Intercept, Salix

Janice Jou, MD, MHS, FAASLD Nothing to disclose.

Mitchell A. Mah'moud, MD, FACG, AGAF, FAASLD Scientific Consulting: Chronic Liver Disease Foundation

Ayse Leyla Mindikoglu, MD, MPH, FAASLD Nothing to disclose.

Kim Olthoff, MD Nothing to disclose

Yuval Patel, MD Scientific Consulting: Intercept

Stacey Prenner, MD Nothing to disclose.

Ryan Taylor, MD, FAASLD Consulting for Equity (e.g. Venture Capital Firms): Abbive, Inc. Speakers Bureau: Gilead Sciences, Inc.

Manish Thapar, MD, FAASLD Commercial Speaker's Bureau: Alnylum Pharmaceuticals

AASLD Governing Board

Carla Brady, MD, MHS, FAASLD Nothing to disclose

Raymond Chung, MD, FAASLD Grant/Research Support: Abbvie, Merck, Boehringer Ingelheim, Gilead, Janssen, BMS, Roche, Synlogic, Kaleido Other: Non-consulting General payment $250, Janssen; Asssociated Research PI payments to institution

Laurie DeLeve, MD, PhD, FAASLD – President Consulting: Daiichi-Sankyo Intellectual Property Rights: Compositions and Methods for Ameliorating Tissue Injury,Enhancing Liver Regeneration and Stem Cell Therapies (sole inventor)(GBC ref.: 6177.132445PCT);2017-230-01 US no. 62/544,589 End-organ selective MMP inhibition enhances bone marrow progenitor cell recruitment

Saul Karpen, MD, PhD, FAASLD Leadership in related society: Co-Chair of recently-formed International Liver Forum for Pediatric Cholestasis Scientific Consulting: Intercept Pharmaceuticals, Vertex, Albireo*, Mirum

W. Ray Kim, MD, FAASLD Consulting: Gilead Stock Options: Durect Grants/Research Support: Gilead, Roche, Genentech

Paul Martin, MD, FAASLD Consulting: ABIM, Up to Date, IQVIA

Kim Olthoff, MD Nothing to disclose

Vijay Shah, MD, FAASLD Intellectual Property Rights: US Patent - NOVEL BRD4 INHIBITORS TO TREAT LIVER DISEASE Consulting: Ambys Medicine, Durect Corporation, Novartis Pharma, AgomAb Therapeutics, Akaza Bioscience Ltd., Generon Shanghai, HepaRegeniX, Intercept Pharmaceuticals, Inc., Mallinckrodt Pharmaceuticals, Surrozen

Grace Su, MD, FAASLD Stock/Stock Options: Spouse- Equity interest in Applied Morphomics, Prenovo Leadership in related society: Member, Clinical Guidelines Committee, AGA

Mary Rinella, MD, FAASLD Consulting: Squibb & Sons, Intercept, Novo Nordisk,Siemens Medical, Amgen, Pfizer, Intercept

Norah Terrault, MD, MPH, FAASLD President-elect Consulting: Asssociated Research PI, CCO Hepatitis, CLDF, Simply Speaking, Gilead Sciences Data Safety Monitoring Board for industry or Commercial Enterprise: Moderna Grants/Research Support: Sciences, GSK, Roche-Genentech, Helio Health, Durect Corp

AASLD Staff Disclosures

Julie Deal Nothing to disclose

Matthew D’Uva Nothing to disclose

Lisa Patterson Nothing to disclose

Colin Syphax Nothing to disclose

Please review the AASLD Privacy Policy before starting this course.
Powered By